Evaluating the Role of Quantitative Computed Tomography Image Feature Analysis in Gynecologic Cancers
Kathleen G. Essel, MD, discusses the role of quantitative imaging feature analysis in gynecologic cancers.
Kathleen G. Essel, MD, a fellow at The University of Oklahoma Stephenson Cancer Center, discusses the role of quantitative computed tomography image feature analysis to predict response to immune checkpoint inhibitors in gynecologic cancers.
This is a new technology that identifies whether or not a patient will respond to treatment based on tumor imaging and RECIST criteria, says Essel. A computer detection scheme can determine which different features are present or absent, then make a score for patient response.
KEYNOTE-A18 Supports Pembrolizumab and CRT as New Standard in High-Risk Cervical Cancer
September 14th 2024Pembrolizumab combined with chemoradiotherapy followed by pembrolizumab monotherapy significantly improved survival compared to chemoradiotherapy alone in patients with high-risk locally advanced cervical cancer.
Read More
Pembrolizumab Plus CCRT Scores in East Asian Subgroup With Cervical Cancer
September 9th 2024Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus concurrent chemoradiotherapy for patients with high-risk, locally advanced cervical cancer in the East Asia subgroup of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
Read More
